Zinger Key Points
- Tilray Brand's Tilray Medical announced the launch of Redecan EU-GMP certified medical cannabis products in Australia.
- Tilray has been present in Australia for years.
- With stocks plunging, steady income is key. Tim Melvin & Ryan Faloona reveal dividend stocks and deep-value plays on April 8. Reserve your spot now.
Tilray Medical, a division of Tilray Brands, Inc. TLRY TLRY announced on Wednesday the launch of Redecan EU-GMP certified medical cannabis products in Australia.
What Happened: The following Redecan products are now available for medical cannabis patients in Australia, including:
- Redecan PC THC28 Purple Churro – 15g
- Redecan SA THC28 Space Age Cake – 15g
Why It Matters: Denise Faltischek, chief strategy officer and head of international at Tilray Brands, praised the move.
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
"The launch of Redecan further expands our medical cannabis portfolios alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and healthcare practitioners to find the optimal therapeutic solutions," Faltischek said.

Jonathan Trodden, director at Tilray Medical Australia, agrees: "We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.”
Tilray has been present in Australia for years. In 2022, the company launched a new medical cannabis e-learning platform for healthcare providers, built on the importance of understanding the benefits derived from medical cannabis use. This effort followed Tilray’s successful introduction of multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of healthcare practitioners in 2021.
Price Action: Tilray's shares traded 0.51% higher at $1.8193 per share during the pre-market session on Wednesday morning.
Read Next:
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!